Catálogo de publicaciones - revistas

<jats:p>Drug companies, biotechs, and Wall Street investors are putting their money down on efforts to unlock the secrets of human DNA. But when will genomics deliver on its promise of next-generation drugs and treatments?</jats:p> <jats:p>RELATED WEB SITES:</jats:p> <jats:p> <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ornl.gov/sci/techresources/Human_Genome/home.html" xlink:type="simple">http://www.ornl.gov/sci/techresources/Human_Genome/home.html</jats:ext-link> A U.S. government-maintained Web page for news, policy guidelines, and ethics discussions centered on the international Human Genome Project. </jats:p> <jats:p> <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www3.techstocks.com/~wsapi/investor/stocktalk-10" xlink:type="simple">http://www3.techstocks.com/~wsapi/investor/stocktalk-10</jats:ext-link> A private site where small investors chat, often with scant insight, about a wide variety of biotech stocks. </jats:p> <jats:p> <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.tradesmart.com/rumor/" xlink:type="simple">http://www.tradesmart.com/rumor/</jats:ext-link> The Biotech Rumor Mill, a gossip zone about biotech companies, much of it anonymous. (See the <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nextwave.org/server-java/SAM/pastrev/rumor.htm" xlink:type="simple">site review</jats:ext-link> in Science's Next Wave.) </jats:p> <jats:p> <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.recap.com/" xlink:type="simple">http://www.recap.com/</jats:ext-link> Recombinant Capital, a San Francisco consulting group directed by Mark Edwards. With detailed analytical information on biotech companies, their capitalization, and past press releases. </jats:p> <jats:p> <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sec.gov/cgi-bin/srch-edgar" xlink:type="simple">http://www.sec.gov/cgi-bin/srch-edgar</jats:ext-link> The U.S. Securities and Exchange Commission's search engine for looking up recent disclosures filed by public companies. </jats:p>

<jats:p>More than a century after Austrian monk Gregor Mendel first detailed how genetic material was passed from one generation to the next, researchers still don't know how many genes we're all walking around with. Expert estimates range from 60,000 to 150,000.</jats:p>

<jats:p>Academics, researchers at older biotech and big pharmaceutical companies, and even some stock analysts worry that the promise of genomics is being oversold. As one prominent researcher puts it, “For a number of genetic diseases, knowing the genes might not help the patient one whit.”</jats:p>

<jats:p>A profile of the founder of Sequana Therapeutics.</jats:p>

<jats:p>A profile of Genset's chief genomics officer.</jats:p>

<jats:p>The key players and companies, and the deal values of their key collaborations</jats:p>

<jats:p>A dusty, old field called “pharmacogenetics,” which attempts to understand why drugs affect different people differently, may revolutionize the way drugs are prescribed in the future.</jats:p>

<jats:p>The secretive policies of many biotechs and pharmaceutical firms have rekindled a smoldering debate over who should control DNA sequence data, and how quickly it should be shared.</jats:p>

<jats:p>Fundamental tensions over control of data have severely strained relations between The Institute for Genomic Research's J. Craig Venter and Human Genome Sciences Inc.'s William Haseltine.</jats:p>